Olympiad Research LP Takes Position in Johnson & Johnson $JNJ

Olympiad Research LP purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,184 shares of the company’s stock, valued at approximately $334,000.

Several other institutional investors and hedge funds also recently bought and sold shares of JNJ. GFG Capital LLC purchased a new stake in Johnson & Johnson in the 2nd quarter worth about $35,000. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson in the first quarter worth approximately $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at $48,000. Harvest Fund Management Co. Ltd bought a new position in Johnson & Johnson in the 1st quarter valued at $52,000. Finally, Pandora Wealth Inc. purchased a new stake in Johnson & Johnson in the first quarter worth $65,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ opened at $195.19 on Friday. The company has a 50 day moving average of $185.46 and a two-hundred day moving average of $169.66. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $196.00. The company has a market cap of $470.27 billion, a price-to-earnings ratio of 18.84, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion during the quarter. As a group, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on JNJ shares. Argus set a $210.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Citigroup raised their target price on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, October 15th. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Finally, HSBC upped their target price on Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Thursday, October 16th. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $200.52.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.